This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Memantine
From Proteopedia
(Difference between revisions)
| Line 2: | Line 2: | ||
Memantine is a medication used to slow the progression of moderate-to-severe Alzheimer's disease. It is believed to work by acting on NMDA receptors, working as pore blockers of these ion channels. See also [https://en.wikipedia.org/wiki/Memantine]. | Memantine is a medication used to slow the progression of moderate-to-severe Alzheimer's disease. It is believed to work by acting on NMDA receptors, working as pore blockers of these ion channels. See also [https://en.wikipedia.org/wiki/Memantine]. | ||
| - | <scene name='96/963765/Overall/1'>Memantine-bound GluN1a-GluN2B NMDA receptors</scene> ([[7sad]]); GluN1a subunits are in cyan, GluN2B subunits are in green, and memantine is in magenta. | + | <scene name='96/963765/Overall/1'>Memantine-bound GluN1a-GluN2B NMDA receptors</scene> ([[7sad]]); GluN1a subunits are in cyan, GluN2B subunits are in green, and memantine is in magenta. <scene name='96/963765/Binding_site/1'>Memantine binding site</scene>. |
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 10:45, 30 April 2023
| |||||||||||
